<DOC>
	<DOCNO>NCT00959140</DOCNO>
	<brief_summary>Stem cell collect sibling donor allogenic transplant contain various type cell . The predominant immune cell call CD3+ T cell . The amount T cell vary vastly donor donor . This study determine standardize CD3+ T cell dose benefit recipient ( patient ) . As well help discover dose standardization cause less variation outcome patient make transplantation predictable complication easy manage .</brief_summary>
	<brief_title>Standardization CD3+ T Cell Dose Patients Receiving Allogeneic Peripheral Blood Stem Cell Transplantation From Matched Related Donors</brief_title>
	<detailed_description>The optimal CD3+ cell dose use allo HSCT unknown . In addition , multiple variable addition CD3+ cell dose affect engraftment , immune reconstitution , GVH GVL patient include recipient age , diagnosis , disease status transplantation , donor/recipient tissue type match , preparative regimen , GVHD prophylaxis . Thus ability produce product fix CD3+ content critical research ultimately definition `` right dose '' CD3+ cell various clinical situation . Patients meet eligibility criterion receive peripheral blood stem cell product original match sibling donor engineer deliver dose 3.0+/-0.5 x107 CD3+ cells/kg recipient body weight . Other component graft manipulate recipient receive total number cell collect exception minimal loss occur process CD3+ T cell isolation .</detailed_description>
	<criteria>1 . Patients must ≥19 year age . 2 . Patients must meet UAB diagnosis disease status criterion clinical appropriateness myeloablative allo HSCT derive ASBMT NCCN guideline . 3 . Patients must 10/10 HLA match sibling ( exclude identical twin ) . All donor evaluate eligibility suitability per standard care accord FACT NMDP guideline . 4 . Adequate organ function : All organ function test do within 28 day study registration . 5 . Cardiac : Left ventricular ejection fraction ( LVEF ) ≥ 50 % MUGA ( Multi Gated Acquisition ) scan echocardiogram . 6 . Pulmonary : FEV1 ( Forced expiratory volume 1 second ) FVC ( Forced vital capacity ) ≥ 50 % predict , DLCO ( alveolar diffusion capacity carbon monoxide ) ( correct hemoglobin ) ≥ 50 % predict . 7 . Renal : The estimated creatinine clearance ( CrCl ) must equal great 60 mL/min/1.73 m2 calculate CockcroftGault Formula 8 . Performance status : Karnofsky ≥ 70 % 9 . Hepatic ( value less consider grade II toxicity per CTCAE ( common terminology criterion adverse event ) Exclusion criterion 1 . Uncontrolled infection , define positive blood culture within 72 hour study entry , evidence progressive infection image study chest CT scan within 14 day registration . 2 . HIV positive patient . 3 . Prior autologous allogeneic transplantation disease . 4 . Scheduled receive nonmyeloablative reduce intensity condition regimen . 5 . High Risk Features associate increase relapse risk poor outcome : 1 . AML/ALL : Biphenotypic feature 2 . AML : Refractory Induction salvage therapy 3 . ALL : Refractory Induction salvage therapy 4 . CML : Active blast crisis 5 . HL : Disease refractory chemotherapy target therapy 6 . NHL : Disease refractory chemotherapy target therapy</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Allo PBSC</keyword>
	<keyword>HSCT</keyword>
	<keyword>Bone Marrow Transplant</keyword>
	<keyword>Allogeneic Bone Marrow Transplant</keyword>
	<keyword>Matched Related Donor Transplant</keyword>
	<keyword>MRD HSCT</keyword>
</DOC>